Merck & Co., Inc. (NYSE:MRK) announced today that its investigational antibody drug conjugate, zilovertamab vedotin, showed ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

By Ludwig Burger FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing foreign-exchange effects and ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Daiichi Sankyo & Merck voluntarily withdraws patritumab deruxtecan BLA to treat locally advanced or metastatic EGFR-mutated NSCLC from US FDA: Basking Ridge, New Jersey Friday, Ma ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

Amid ongoing uncertainty around funding for the NIH and what it could mean for U.S. innovation, a top Merck executive ...

the Rahway-based company announced April 29. The Merck Wilmington Biotech facility will house laboratory, manufacturing and warehouse capabilities for the launch and commercial production of ...

In early 2024 Merck also secured approvals for a new “Building 41” to be located toward the center of the company’s 320-acre complex, a new lab analysis and testing building to be built on ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, manufacturing and warehouse capabilities to produce next-generation biologics and ...